RecruitingNCT05196087

Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)

Sponsor

University Health Network, Toronto

Enrollment

500 participants

Start Date

Jul 20, 2022

Study Type

OBSERVATIONAL

Conditions

Breast Cancer Melanoma Gastrointestinal Neuroendocrine Tumor

Summary

Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing an AI-based monitoring platform that uses non-invasive tests (no needles or biopsies) to track cancer patients after curative treatment and detect any signs of cancer returning early. **You may be eligible if...** - You are 18 or older - You have been diagnosed with a solid tumor (confirmed by biopsy or pathology) - You have early-stage or locally advanced cancer that has been treated with curative intent (aimed at eliminating the cancer) **You may NOT be eligible if...** - There are no exclusion criteria listed for this study — most patients with early or locally advanced solid tumors may qualify Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05196087

Related Trials

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT052833304 locations

Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI)

NCT068852031 location